I had wanted to write this follow-up to my original article prior to La Jolla Pharmaceutical's (NASDAQ:LJPC) Phase II data readout, but given I have been slugging through a particularly brutal "busy season" at work, this did not happen. While some of what I have written below has been analyzed by others, I do think it prudent to provide some of my analysis and thought process over the past few weeks. I, of course, want to provide my opinion on some positive developments at the company since January, as well as my thoughts on the results of the GCS-100 Phase II data presented at the recent Roth Conference.
Reverse Split and Uplisting
Before I delve into data,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|